Compile Data Set for Download or QSAR
Report error Found 33 Enz. Inhib. hit(s) with all data for entry = 3152
TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330233(US9663543, Compound 9 | ethyl hydrogen 3-acetyl-1-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330235(US9663543, Compound 11 | ethyl 1-(2-((2S,4R)-2-(3-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330236(US9663543, Compound 12 | 1-(2-((2S,4R)-2-(3-chloro...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330229(US9663543, Compound 5 | diethyl 3-acetyl-1-(2- ((2...)
Affinity DataIC50: 5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330251(US9663543, Compound 27 | 3-acetyl-1-(2-((2S,4R)-2-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330244(US9663543, Compound 20 | dibutyl 3-acetyl-1-(2- ((...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330245(US9663543, Compound 21 | butyl hydrogen 3-acetyl-1...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330246(US9663543, Compound 22 | ((3-acetyl-1-(2-((2S,4R)-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330247(US9663543, Compound 23 | ethyl 3-acetyl-1-(2- ((2S...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330248(US9663543, Compound 24 | ethyl 3-acetyl-1-(2- ((2S...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330249(US9663543, Compound 25 | 3-acetyl-1-(2-((2S,4R)-2-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330250(US9663543, Compound 26 | ((3-acetyl-1-(2-((2S,4R)-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330241(US9663543, Compound 17 | diethyl 3-carbamoyl-1-(2-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330252(US9663543, Compound 28 | ((3-acetyl-1-(2-((2S,4R)-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330253(US9663543, Compound 29 | 2,2,2-trifluoroethyl hydr...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330254(US9663543, Compound 30 | diethyl 3-acetyl-1-(2- ((...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330255(US9663543, Compound 31 | 3-acetyl-1-(2-((2S,4R)-2-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330256(US9663543, Compound 32 | 1-(2-((2S,4R)-2-(3-chloro...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330257(US9663543, Compound 33 | diphenyl 3-acetyl-1-(2- (...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330243(US9663543, Compound 19 | bis(2,2,2-trifluoroethyl)...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330242(US9663543, Compound 18 | 3-carbamoyl-1-(2-((2S,4R)...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330225(US9663543, Compound 1 | diethyl 3-acetyl-1-(2- ((2...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330240(US9663543, Compound 16 | 3-carbamoyl-1-(2-((2S,4R)...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330239(US9663543, Compound 15 | diethyl 3-carbamoyl-1-(2-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330238(US9663543, Compound 14 | 1-(2-((2S,4R)-2-(3-chloro...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330237(US9663543, Compound 13 | methyl 1-(2-((2S,4R)-2-(3...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330234(US9663543, Compound 10 | 3-acetyl-1-(2-((2S,4R)-2-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330232(US9663543, Compound 8 | diethyl 3-acetyl-1-(2- ((2...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330231(US9663543, Compound 7 | 3-acetyl-1-(2- ((2S,3aR,6a...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330230(US9663543, Compound 6 | ((3-acetyl-1-(2-((2S,4R)-2...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330228(US9663543, Compound 4 | ((3-acetyl-1-(2-((2S,4R)-2...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330227(US9663543, Compound 3 | 3-acetyl-1-(2-((2S,4R)-2-(...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330226(US9663543, Compound 2 | ethyl hydrogen 3-acetyl-1-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent